natgillin/translations-raw huggingface dataset:
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from tigecycline therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. 
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja s tigeciklinom, pri čemer je treba upoštevati prednosti dojenja za otroka in prednosti zdravljenja za mater.
• If you have blockage of the bile ducts (cholestasis). 
• če imate zaporo žolčevodov (holestazo).
During treatment with Tygacil: 
Med zdravljenjem z zdravilom Tygacil:
* single dose AUC0-∞, multiple dose AUC0-12h 
* AUC0-∞ pri enkratnem odmerku, AUC0-12h pri večkratnih odmerkih
The diagnosis of acute pancreatitis should be considered in patients taking tigecycline who develop clinical symptoms, signs, or laboratory abnormalities suggestive of acute pancreatitis. 
Na diagnozo akutnega pankreatitisa moramo pomisliti pri bolnikih, ki prejemajo tigeciklin, pri katerih se razvijejo klinični simptomi, znaki ali laboratorijske nenormalnosti, ki kažejo na akutni pankreatitis.
For anaerobic bacteria there is clinical evidence of efficacy in polymicrobial intra-abdominal infections, but no correlation between MIC values, PK/PD data and clinical outcome. 
Za anaerobne bakterije obstajajo klinični dokazi o učinkovitosti pri polimikrobnih intraabdominalnih okužbah, vendar ni nikakršne korelacije med vrednostmi MIC, podatki o farmakokinetiki in farmakodinamiki in kliničnim izidom.
Abdominal pain is commonly reported in children as it is in adults. 
Pri otrocih so bolečino v trebuhu pogosteje poročali kot pri odraslih.
In vitro, tigecycline is neither a competitive inhibitor nor an irreversible inhibitor of CYP450 enzymes (see section 5.2). 
In vitro tigeciklin ni niti kompetitiven inhibitor niti ireverzibilen inhibitor encimov CYP450 (glejte poglavje 5.2).
Decreased susceptibility in Acinetobacter baumannii has been attributed to the overexpression of the AdeABC efflux pump. 
Zmanjšano občutljivost pri Acinetobacter baumannii so pripisali čezmerni ekspresiji AdeABC iztočne črpalke.
Pharmacotherapeutic group: Antibacterials for systemic use, tetracyclines, ATC code: J01AA12. 
Farmakoterapevtska skupina: zdravila za sistemsko zdravljenje bakterijskih infekcij, tetraciklini, oznaka ATC: J01AA12.
Experience in the use of tigecycline for treatment of infections in patients with severe underlying diseases is limited. 
Izkušenj z uporabo tigeciklina za zdravljenje okužb pri bolnikih s hudimi osnovnimi boleznimi je malo.
No loading dose was administered in these studies. 
V teh študijah ni bilo polnilnega odmerka.
Infections and infestations sepsis/septic shock, pneumonia, abscess, infections 
Infekcijske in parazitske bolezni sepsa/septični šok, pljučnica, absces, okužbe
Tygacil should be used only in situations where other alternative antibiotics are not suitable (see sections 4.4, 4.8 and 5.1). 
Zdravilo Tygacil se sme uporabiti le v primerih, ko drugi antibiotiki niso primerni (glejte poglavja 4.4, 4.8 in 5.1).
Talk to your doctor about the need for an additional method of contraception while receiving Tygacil. 
Pogovorite se z zdravnikom o tem, ali potrebujete med zdravljenjem z zdravilom Tygacil še dodatno kontracepcijsko metodo.
The in vitro plasma protein binding of tigecycline ranges from approximately 71 % to 89 % at concentrations observed in clinical studies (0.1 to 1.0 mcg/ml). 
Vezava tigeciklina na plazemske beljakovine in vitro sega od približno 71 % do 89 % pri koncentracijah, ki so jih opazovali v kliničnih študijah (0,1 do 1,0 g/ml).
Species for which acquired resistance may be a problem Gram-negative Aerobes 
Vrste, pri katerih je lahko problematična pridobljena odpornost Gramnegativni aerobi
Blood and lymphatic system disorders prolonged activated partial thromboplastin time (aPTT), prolonged prothrombin time (PT) 
Bolezni krvi in limfatičnega sistema podaljšan aktivirani parcialni tromboplastinski čas (aPTČ), podaljšan protrombinski čas (PČ)
For intravenous use after reconstitution and dilution. 
za intravensko uporabo po rekonstituciji in redčenju
All patients received IV tigecycline for a minimum of 3 consecutive days to a maximum of 14 consecutive days, with the option to be switched to an oral antibiotic on or after day 4. 
vsaj 3 zaporedne dni do največ 14 zaporednih dni z možnostjo prehoda na peroralni antibiotik 4. dan ali pozneje.
Patients with severe underlying disease, such as those that were immunocompromised, patients with decubitus ulcer infections, or patients that had infections requiring longer than 14 days of treatment (for example, necrotizing fasciitis), were not enrolled. 
Bolniki s hujšo osnovno boleznijo, na primer imunsko oslabljeni bolniki, bolniki z okužbami preležaninskih razjed ali bolniki z okužbami, pri katerih je bilo potrebno zdravljenje, daljše od 14 dni (na primer nekrotizirajoči fasciitis), niso bili vključeni.
Patients with severe hepatic impairment (Child Pugh C) should be treated with caution and monitored for treatment response (see sections 4.4 and 5.2). 
Bolnike s hudo okvaro jeter (razred C po Child-Pughovi lestvici) je treba zdraviti previdno in spremljati odziv na zdravljenje (glejte poglavji 4.4 in 5.2).
Skin and subcutaneous tissue disorders pruritus, rash severe skin reactions, including Stevens-Johnson Syndrome 
Bolezni kože in podkožja pruritus, izpuščaj hude kožne reakcije, vključno s StevensJohnsonovim sindromom
Tigecycline is able to overcome the two major tetracycline resistance mechanisms, ribosomal protection and efflux. 
Tigeciklin je sposoben premagati oba poglavitna mehanizma odpornosti proti tetraciklinom, ribosomsko zaščito in iztok.
The summary of clinical response in the modified intent-to-treat (mITT) population results is shown in the following table. 
Povzetek kliničnega odziva v modificirani populaciji, ki so jo nameravali zdraviti (mITT - modified intent-totreat), je prikazan v spodnji preglednici.
If you develop diarrhoea during or after your treatment, tell your doctor at once. 
Če se vam razvije driska med zdravljenjem ali po njem, to takoj povejte zdravniku.
At 4 times the minimum inhibitory concentration (MIC), a 2-log reduction in colony counts was observed with tigecycline against Enterococcus spp., Staphylococcus aureus, and Escherichia coli. 
Pri koncentraciji, ki je bila štirikrat višja od minimalne inhibicijske koncentracije (MIC), so pri tigeciklinu opazovali zmanjšanje 2-log števila kolonij proti Enterococcus spp., Staphylococcus aureus in Escherichia coli.
Tygacil is not to be used in children less than 8 years of age due to the lack of data on safety and efficacy in this age group and because it may induce permanent dental defects such as staining on the developing teeth. 
Zdravilo Tygacil se ne sme uporabljati pri otrocih, mlajših od 8 let, zaradi pomanjkanja podatkov o varnosti in učinkovitosti v tej starostni skupini in ker lahko povzroča trajne okvare zob, na primer obarvanost razvijajočih se zob.
• Your doctor will monitor you closely for the development of any other bacterial infections. 
• vaš zdravnik bo skrbno spremljal, če se je pri vas pojavila še kakšna druga bakterijska okužba.
• Low fibrinogen levels in the blood (a protein involved in blood clotting) 
• nizke ravni fibrinogena v krvi (beljakovine, vključene v strjevanje krvi)
Tigecycline is administered only by intravenous infusion over 30 to 60 minutes (see sections 4.4 and 6.6). 
Tigeciklin se daje samo z intravensko infuzijo, ki teče 30 do 60 minut (glejte poglavji 4.4 in 6.6).
No specific information is available on the treatment of overdosage. 
O zdravljenju prevelikega odmerjanja specifičnih podatkov ni na voljo.
• Sepsis (severe infection in the body and blood stream)/septic shock (serious medical condition which can lead to multiple organ failure and death as a result of sepsis) 
• sepsa (huda okužba v telesu in krvnem obtoku)/septični šok (težko zdravstveno stanje, ki lahko kot posledica sepse povzroči odpoved več organov in smrt)
hypofibrinogenaemia 
hipofibrinogenemija
Do not take any diarrhoea medicine without first checking with your doctor. 
Ne vzemite zdravil proti driski, ne da bi prej vprašali zdravnika;
This consists of severe, persistent or bloody diarrhoea associated with abdominal pain or fever, which can be a sign of serious bowel inflammation, which may occur during or after your treatment. 
Prepoznamo ga po hudi, trdovratni ali krvavi driski, povezani z bolečinami v trebuhu ali vročino, ki je lahko znak resnega črevesnega vnetja in se lahko pojavi med vašim zdravljenjem ali po koncu zdravljenja.
Tygacil is an antibiotic of the glycylcycline group that works by stopping the growth of bacteria that cause infections. 
Zdravilo Tygacil je antibiotik glicilciklinske skupine, ki deluje tako, da zaustavi rast bakterij, ki povzročajo okužbe.
The use of tigecycline may result in overgrowth of non-susceptible organisms, including fungi. 
Uporaba tigeciklina lahko povzroči razraščanje neobčutljivih organizmov, med drugim glivic.
In patients (including paediatrics) with severe hepatic impairment (Child Pugh C), the dose of tigecycline should be reduced by 50%. 
Pri bolnikih (vključno z otroci) s hudo okvaro jeter (razred C po Child-Pughovi lestvici) je treba odmerek tigeciklina zmanjšati za 50 %.
In all Phase 3 and 4 (cSSTI and cIAI) studies, death occurred in 2.4 % (54/2216) of patients receiving tigecycline and 1.7% (37/2206) of patients receiving active comparators. 
V vseh študijah faze 3 in 4 (študijah cSSTI ter študijah cIAI) je umrlo 2,4 % (54/2.216) bolnikov, ki so prejemali tigeciklin, in 1,7 % (37/2.206) bolnikov, ki so prejemali primerjalne učinkovine.
Animal and human pharmacokinetic studies have demonstrated that tigecycline readily distributes to tissues. 
Farmakokinetične študije na živalih in ljudeh so pokazale, da se tigeciklin z lahkoto porazdeljuje v tkiva.
Each vial contains lactose monohydrate. 
Ena viala vsebuje laktozo monohidrat.
• Abscess (collection of pus), infections 
• abscesi (ognojki), okužbe
Patients should be carefully monitored during therapy (see section 4.8). 
Bolnike moramo med zdravljenjem skrbno spremljati (glejte poglavje 4.8).
Dose Normalized to 1 mg/kg Mean ± SD Tigecycline Cmax and AUC in Children Age (yr) 
Odmerek normaliziran na povprečno 1 mg/kg ± SD, Cmax in AUC tigeciklina pri otrocih starost (let)
No new or unexpected safety concerns were observed with tigecycline in these studies. 
V omenjenih študijah niso opazili novih ali nepričakovanih podatkov o varnosti tigeciklina.
The pH is adjusted with hydrochloric acid, and if necessary sodium hydroxide. 
pH je uravnan s klorovodikovo kislino in po potrebi z natrijevim hidroksidom.
In general, tigecycline is considered bacteriostatic. 
Na splošno velja, da je tigeciklin bakteriostatik.
If pancreatitis develops, treatment with tigecycline should be discontinued. 
Če se pojavi pankreatitis, je treba zdravljenje s tigeciklinom prekiniti.
These vials are distributed to the hospital in a ten tray pack. 
Te viale dobavljajo bolnišnicam na podstavkih z desetimi vialami.
Tigecycline has decreased in vitro activity against Proteus, Providencia, and Morganella spp. 
^)Tigeciklin ima zmanjšano aktivnost in vitro proti družinam Proteus, Providencia in Morganella spp.
Tigecycline is a substrate of P-gp based on an in vitro study using a cell line overexpressing P-gp. 
Tigeciklina je substrat P-gp, kar temelji na študiji in vitro, opravljeni na celični liniji s prekomerno izraženim P gp.
• Laboratory measurements of decreased ability to form blood clots 
• laboratorijsko ugotovljena zmanjšana sposobnost strjevanja krvi
In vitro studies using Caco-2 cells indicate that tigecycline does not inhibit digoxin flux, suggesting that tigecycline is not a P-glycoprotein (P-gp) inhibitor. 
In vitro študije s celicami Caco-2 kažejo, da tigeciklin ne zavira toka digoksina, kar kaže, da tigeciklin ni inhibitor P-glikoproteina (P-gp).
• If you have poor or slow wound healing. 
• če se vam rane slabo ali počasi celijo;
Very limited safety data were available from two PK studies (see section 5.2). 
Na voljo je le malo podatkov o varnosti iz dveh farmakokinetičnih študij (glejte poglavje 5.2).
Available pharmacodynamic/toxicological data in animals have shown excretion of tigecycline/metabolites in milk (see section 5.3). 
Razpoložljivi farmakodinamični/toksikološki podatki pri živalih kažejo na izločanje tigeciklina/presnovkov v mleko (glejte poglavje 5.3).
In humans, the steady-state volume of distribution of tigecycline averaged 500 to 700 L (7 to 9 L/kg), indicating that tigecycline is extensively distributed beyond the plasma volume and concentrates into tissues. 
Pri ljudeh je bil volumen porazdelitve tigeciklina v stanju dinamičnega ravnovesja povprečno 500 do 700 l (7 do 9 l/kg), kar kaže, da se tigeciklin obsežno prerazporedi iz plazemskega prostora in se kopiči v tkivih.
Intravenous administration of tigecycline at a single dose of 300 mg over 60 minutes in healthy volunteers resulted in an increased incidence of nausea and vomiting. 
Intravensko dajanje tigeciklina zdravim prostovoljcem v enkratnem 300-miligramskem odmerku v času 60 minut je bilo povezano z večjo pojavnostjo navzee in bruhanja.
In clinical studies in complicated skin and soft tissue infections (cSSTI), complicated intra-abdominal infections (cIAI), diabetic foot infections, nosocomial pneumonia and studies in resistant pathogens, a numerically higher mortality rate among tigecycline treated patients has been observed as compared to the comparator treatment. 
V kliničnih študijah pri zapletenih okužbah kože in mehkih tkiv (cSSTI - complicated skin and soft tissue infections), zapletenih intraabdominalnih okužbah (cIAI - complicated intra-abdominal infections), okužbah diabetičnega stopala, bolnišnični pljučnici in študijah pri rezistentnih patogenih so opazili številčno višjo stopnjo umrljivosti pri bolnikih, zdravljenih s tigeciklinom, v primerjavi z bolniki, ki so prejemali primerjalna zdravila.
If you are allergic to tetracycline class antibiotics (e.g., minocycline, doxycycline, etc.), you may be allergic to tigecycline. 
Če ste alergični na tetraciklinsko skupino antibiotikov (na primer minociklin, doksiciklin itn.), ste mogoče alergični tudi na tigeciklin.
Decreased susceptibility in both groups has been attributed to the overexpression of the non-specific AcrAB multi-drug efflux pump. 
Zmanjšano občutljivost pri obeh skupinah so pripisali čezmerni ekspresiji nespecifične AcrAB multimedikamentozne iztočne črpalke.
Biliary excretion accounts for approximately 50 % of the total tigecycline excretion. 
Izločanje z žolčem predstavlja okrog 50 % celotnega izločanja tigeciklina.
thrombocytopenia, increased international normalised ratio (INR) 
trombocitopenija, zvečano internacionalno normalizirano razmerje (INR)
In in vitro studies, no antagonism has been observed between tigecycline and other commonly used antibiotic classes. 
V raziskavah in vitro niso opazili antagonizma med tigeciklinom in drugimi skupinami antibiotikov, ki se pogosto uporabljajo.
As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable. 
Če je na lokalnem območju prevalenca odpornosti tolikšna, da je koristnost zdravila vsaj pri nekaterih vrstah okužb vprašljiva, po potrebi poiščite nasvet strokovnjaka.
In vitro studies in human liver microsomes indicate that tigecycline does not inhibit metabolism mediated by any of the following 6 cytochrome P450 (CYP) isoforms: 1A2, 2C8, 2C9, 2C19, 2D6, and 3A4 by competitive inhibition. 
Raziskave v mikrosomih človeških jeter in vitro kažejo, da tigeciklin ne zavira presnove, ki jo posreduje katerakoli od naslednjih šestih izoform citokroma P450 (CYP): 1A2, 2C8, 2C9, 2C19, 2D6, in 3A4, s kompetitivno inhibicijo.
In addition, tigecycline did not show NADPH-dependency in the inhibition of CYP2C9, CYP2C19, CYP2D6 and CYP3A, suggesting the absence of mechanism-based inhibition of these CYP enzymes. 
Poleg tega tigeciklin pri inhibiciji CYP2C9, CYP2C19, CYP2D6 in CYP3A ni kazal odvisnosti od NADPH, kar kaže na odsotnost encimskega mehanizma inhibicije teh CYP encimov.
The other ingredients are lactose monohydrate, hydrochloric acid, and sodium hydroxide. 
Druge sestavine zdravila so laktoza monohidrat, klorovodikova kislina in natrijev hidroksid.
In clinical trials, the most common medicinal product-related treatment emergent adverse reactions were reversible nausea (21 %) and vomiting (13 %), which usually occurred early (on treatment days 1-2) and were generally mild or moderate in severity. 
V kliničnih preskušanjih sta bila najpogostejša neželena učinka, ki sta se pojavila v zvezi z zdravljenjem z zdravilom, reverzibilna navzea (21 %) in bruhanje (13 %), ki sta se navadno pojavila v začetku zdravljenja (prvi ali drugi dan zdravljenja) in sta bila na splošno blaga do zmerna.
In rats receiving single or multiple doses of 
Pri podganah, ki so prejele bodisi enkraten odmerek bodisi po več odmerkov
Powder for solution for infusion (powder for infusion). 
prašek za raztopino za infundiranje (prašek za infuzijo)
These effects were observed at exposures of 14 and 3 times the human daily dose based on the AUC in rats and dogs respectively. 
Te učinke so opazovali pri izpostavljenosti, ki je bila 14-krat oziroma 3-krat večja od dnevnega odmerka za ljudi na podlagi AUC pri podganah oziroma psih.
Concomitant administration of tigecycline and warfarin (25 mg single-dose) to healthy subjects resulted in a decrease in clearance of R-warfarin and S-warfarin by 40 % and 23 %, and an increase in AUC by 68 % and 29 %, respectively. 
Sočasno dajanje tigeciklina in varfarina (v enkratnem 25-miligramskem odmerku) zdravim osebam je povzročilo zmanjšanje očistka R-varfarina in S-varfarina za 40 % oziroma 23 % in zvečanje AUC za 68 % oziroma 29 %.
Concurrent use of antibiotics with oral contraceptives may render oral contraceptives less effective. 
Sočasna uporaba antibiotikov s peroralnimi kontraceptivi lahko zmanjša učinkovitost peroralnih kontraceptivov.
C-labelled tigecycline indicate that tigecycline is excreted readily via the milk of lactating rats. 
C, kažejo, da se tigeciklin z lahkoto izloča preko mleka doječih podgan.
• Low protein levels in the blood 
• znižana raven beljakovin v krvi
Limited experience is also available in treating patients with concurrent bacteraemia (5.6 %). 
Na voljo je tudi malo izkušenj z zdravljenjem bolnikov s sočasno bakteriemijo (5,6 %).
AST and ALT abnormalities in tigecycline-treated patients were reported more frequently in the post therapy period than in those in comparator-treated patients, which occurred more often on therapy. 
O nenormalnostih AST in ALT pri bolnikih, zdravljenih s tigeciklinom, so pogosteje poročali v obdobju po končanem zdravljenju kot pri bolnikih, zdravljenih s primerjalnim zdravilom, pri katerih so se le-te pogosteje pojavljale med zdravljenjem.
Inherently resistant organisms 
Naravno odporni organizmi
Other medicines and Tygacil Tell your doctor if you are taking, have recently taken or might take any other medicines. 
Obvestite zdravnika, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katerokoli drugo zdravilo.
Pathogens of the family Proteeae (Proteus spp., Providencia spp., and Morganella spp.) 
Patogeni družine Proteeae (Proteus spp., Providencia spp.
Bone discolouring was observed in rats which was not reversible after two weeks of dosing. 
Pri podganah so opazili obarvanje kosti, ki po dveh tednih dajanja zdravila ni bilo več reverzibilno.
There were a limited number of patients with severe underlying disease such as immunocompromised patients, patients with APACHE II scores  15 (3.3 %), or with surgically apparent multiple intra-abdominal abscesses (11.4 %). 
Majhno število bolnikov je imelo hujšo osnovno bolezen, na primer imunsko oslabljeni bolniki, bolniki z ocenami >15 po lestvici APACHE II (3,3 %) ali s kirurško ugotovljenimi multiplimi intraabdominalnimi abscesi (11,4 %).
A limited number of patients were enrolled with co-morbid factors such as diabetes (25.8 %), peripheral vascular disease (10.4 %), intravenous substance abuse (4.0 %), and HIVpositive infection (1.2 %). 
Vključeno je bilo majhno število bolnikov s sočasnimi dodatnimi bolezenskimi dejavniki, na primer sladkorno boleznijo (25,8 %), boleznimi perifernega žilja (10,4 %), intravensko zlorabo substanc (4,0 %) in okužbo z virusom HIV (1,2 %).
In clinical pharmacology studies using the therapeutic dosage regimen of 100 mg followed by 50 mg q12h, serum tigecycline steady-state Cmax was 866±233 ng/ml for 30-minute infusions and 634±97 ng/ml for 60-minute infusions. 
V kliničnofarmakoloških študijah, v katerih so uporabljali shemo terapevtskega odmerjanja 100 mg, nato pa 50 mg vsakih 12 ur, je bila serumska Cmax tigeciklina v stanju dinamičnega ravnovesja 866 ± 233 ng/ml pri 30-minutnih infuzijah in 634 ± 97 ng/ml pri 60-minutnih infuzijah.
No data are available on whether tigecycline can cross the blood-brain barrier in humans. 
Ni podatkov o morebitnem prehajanju tigeciklina skozi krvno-možgansko pregrado pri ljudeh.
The steady-state AUC0-12h was 2349±850 ng•h/ml. 
AUC0-12h v stanju dinamičnega ravnovesja je bila 2349 ± 850 ng•h/ml.
There were no clinically relevant differences in the clearance of tigecycline between men and women. 
Očistek tigeciklina se med moškimi in ženskami ni klinično pomembno razlikoval.
Underlying diseases 
Osnovne bolezni
A dosing regimen of 1.2 mg/kg of tigecycline every 12 hours (to a maximum dose of 50 mg every 12 hours) for children aged 8 to <12 years and of 50 mg every 12 hours for adolescents aged 12 to <18 years would likely result in exposures comparable to those observed in adults treated with the approved dosing regimen. 
Shema odmerjanja 1,2 mg/kg tigeciklina vsakih 12 ur (do največjega odmerka 50 mg vsakih 12 ur) pri otrocih, starih od 8 do < 12 let, in 50 mg vsakih 12 ur pri mladostnikih, starih od 12 do < 18 let, bi verjetno privedla do izpostavljenosti, primerljive tistim pri odraslih, zdravljenih z odobreno shemo odmerjanja.
The following active substances should not be administered simultaneously through the same Y-site as tigecycline: Amphotericin B, amphotericin B lipid complex, diazepam, esomeprazole, omeprazole and intravenous solutions that could result in an increase of pH above 7. 
Naslednjih učinkovin ni dovoljeno injicirati sočasno skozi isti podaljšek Y kot tigeciklin: amfotericin B, amfotericin B v obliki lipidnega kompleksa, diazepam, esomeprazol, omeprazol in intravenske raztopine, ki bi lahko povzročile zvišanje pH nad 7.
• Low platelet levels in the blood(which may lead to an increased bleeding tendency and bruising/haematoma) 
• znižana koncentracija krvnih ploščic v krvi (ki lahko zveča nagnjenost h krvavitvam in povzroči modrice/hematome)
Clinical experience in the use of tigecycline for the treatment of infections in paediatric patients aged 8 years and older is very limited (see sections 4.8 and 5.1). 
Kliničnih izkušenj z uporabo tigeciklina za zdravljenje okužb pri pediatričnih bolnikih, starih 8 let ali več, je zelo malo (glejte poglavji 4.8 in 5.1).
Patients who develop superinfections, in particular nosocomial pneumonia, appear to be associated with poorer outcomes. 
Kaže, da imajo bolniki, pri katerih se razvijejo superinfekcije, zlasti bolnišnična pljučnica, slabši izid zdravljenja.
Tigecycline, a glycylcycline antibiotic, inhibits protein translation in bacteria by binding to the 30S ribosomal subunit and blocking entry of amino-acyl tRNA molecules into the A site of the ribosome. 
Glicilciklinski antibiotik tigeciklin inhibira prepisovanje beljakovin z ribonukleinske kisline (RNA) pri bakterijah, tako da se veže na ribosomsko podenoto 30S in blokira vstop aminoacilnih molekul tRNA na mesto A na ribosomu.
• Jaundice (yellow coloration of the skin), inflammation of the liver 
• zlatenica (rumeno obarvanje kože), vnetje jeter
Population PK analysis of both studies identified body weight as a covariate of tigecycline clearance in children aged 8 years and older. 
Analiza populacijske farmakokinetike je v obeh študijah pokazala, da je telesna masa sospremenljivka očistka tigeciklina pri otrocih, starih 8 let ali več.